Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients.
Vicente-Valor J, Escudero-Vilaplana V, Collado-Borrell R, López-López C, Villanueva-Bueno C, Revuelta-Herrero JL, Ruiz-Briones P, Somoza-Fernández B, Herranz A, Sanjurjo M. Vicente-Valor J, et al. Among authors: ruiz briones p. J Oncol Pharm Pract. 2022 Jul;28(5):1259-1263. doi: 10.1177/10781552221074621. Epub 2022 Jan 17. J Oncol Pharm Pract. 2022. PMID: 35037798
Possible heart failure caused by osimertinib in a lung cancer patient.
Ruiz-Briones P, Escudero-Vilaplana V, Collado-Borrell R, Vicente-Valor J, Alvarez R, Villanueva-Bueno C, Narrillos-Moraza Á, Herranz A, Sanjurjo M. Ruiz-Briones P, et al. J Oncol Pharm Pract. 2023 Jun;29(4):1015-1020. doi: 10.1177/10781552221143787. Epub 2022 Dec 8. J Oncol Pharm Pract. 2023. PMID: 36480925
Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare.
Romero-Jimenez R, Escudero-Vilaplana V, Chamorro-de-Vega E, Ais-Larisgoitia A, Lobato-Matilla E, Somoza-Fernández B, Ruiz-Briones P, González C, Baniandrés O, Menchén L, Lobo-Rodríguez C, Herranz A, Sanjurjo M. Romero-Jimenez R, et al. Among authors: ruiz briones p. Front Immunol. 2022 Jul 28;13:915578. doi: 10.3389/fimmu.2022.915578. eCollection 2022. Front Immunol. 2022. PMID: 35967330 Free PMC article.
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy.
Ramos-Ruperez E, Escudero-Vilaplana V, Ruiz-Briones P, Collado-Borrell R, Villanueva-Bueno C, Revuelta-Herrero JL, González-Haba E, Garcia-Gonzalez X, Ibañez-Garcia S, Perez-Ramirez S, Zatarain-Nicolás E, Herranz A, Sanjurjo M. Ramos-Ruperez E, et al. Among authors: ruiz briones p. Front Oncol. 2023 Aug 25;13:1220305. doi: 10.3389/fonc.2023.1220305. eCollection 2023. Front Oncol. 2023. PMID: 37692846 Free PMC article.
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.
Chamorro-de-Vega E, Rodriguez-Gonzalez CG, Manrique-Rodríguez S, Lobato-Matilla E, García-Moreno F, Olmedo M, Correa-Rocha R, Valerio M, Aldámiz-Echevarria T, Machado M, Sancho-Gonzalez M, Lopez-Bernaldo-de-Quirós JC, Ruiz-Briones P, Romero-Jiménez R, Sarobe-González C, Gimenez-Manzorro A, Collado-Borrell R, Fernandez-Llamazares CM, Revuelta-Herrero JL, Somoza-Fernandez B, Garcia-Sanchez S, Taladriz-Sender I, Bouza E, Herranz A, Muñoz P, Sanjurjo M. Chamorro-de-Vega E, et al. Among authors: ruiz briones p. Expert Rev Clin Pharmacol. 2021 Feb;14(2):249-260. doi: 10.1080/17512433.2021.1875819. Epub 2021 Jan 26. Expert Rev Clin Pharmacol. 2021. PMID: 33499687 Free PMC article.